To date, two CD19-CAR-T cell therapies have been approved for the treatment of acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) [21]. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.